1 Testosterone Replacement Therapy & Monitoring in HIV Infected Men Adam B. Murphy, MD, MBA, MSCI October 29, 2014
2 Acknowledgement Ramona Bhatia MD (HIV Research Fellow, First Author) Chad Achenbach MD (HIV Researcher, senior author) James L. Raper, Gabriel Chamie, Mari M. Kitahata, Daniel R. Drozd, Kenneth Mayer, Sonia Napravnik, Richard Moore the Centers for AIDS Research (CFAR) Network of Integrated Clinical Systems (CNICS)
3 Support Creative and Novel Ideas in HIV Research (CNIHR) Award from the US National Institutes of Health (NIH) Office of AIDS Research NIH-funded Centers for AIDS Research[grant number ]; the National Institute of Allergy and Infectious Diseases at the NIH[grant numbers R24 AI and P30 AI and P30 AI50410], with a supplement from the National Cancer Institute; and the National Center for Advancing Translational Sciences at the NIH[grant number KL2 TR000421].
4 Background Global testosterone sales have increased 12-fold over the last decade US is the 2 nd leading consumer worldwide. Androgen use tripled from in the US, with 2.9% of men over 40 years of age on testosterone replacement therapy (TRT). Establishing biochemical testosterone deficiency is recommended before TRT initiation, yet up to 83% of men on TRT lack pre-treatment testosterone measurements.
5 Background 2 TRT may increase the risk of cardiovascular events[7, 8], including myocardial infarction[9, 10], stroke, thrombosis, and death. HIV is associated with testosterone deficiency in 20-70% of men, despite successful antiretroviral therapy (ART)[3,13] HIV associated hypogonadism is expected to increase as this population ages
6 Diagnosis in men with signs & symptoms & unequivocally low serum Testosterone level
7 Diagnostic evaluation of TD
8 Signs & Symptoms
9 Confirmation Confirm the diagnosis by repeating measurement of morning total testosterone. Can add free or bioavailable testosterone in men with low normal levels or where SHBG abnormality is suspected.
10 If testosterone deficient Primary vs. Secondary If deficient check LH and FSH If high Primary TD Check: Karyotype If low to normal Secondary TD Prolactin, Iron Saturation, pituitary function tests and MRI sella turcica to evaluate for secondary hypogonadism Refer to Endocrinology if abnormal otherwise treat
12 Do not start in men with Breast or Prostate cancer Abnormal rectal exam or PSA Hematocrit > 50% Severe sleep apnea (untreated) Severe LUTS (>19 IPSS) Poorly controlled heart failure AAs & men with Fam History and PSA >3ng/ml should be referred to urologists first
13 Treatment Aim for mid-normal range ng/ml high & low levels predispose to side effects, residual symptoms, likely PCa and cardiovascular disease Need to be monitored (varies by treatment type) PSA at baseline and at 3-6 months, then per guidelines
14 Prostate Cancer Can give TRT if clinically localized prostate cancer post prostatectomy with stable PSA for 2 years.
15 Testosterone replacement therapy among HIV-infected men in the CFAR Network of Integrated Clinical Systems (CNICS). AIDS. Accepted. HIV CONCISE COMMUNICATION Testosterone Hypogonadism Men's Health Patient Monitoring Testosterone Replacement Therapy (TRT) Authors declare no conflicts of interest
16 Objectives The objectives of this study were to determine: the rate of testosterone replacement therapy (TRT) initiation TRT predictors patterns of monitoring in HIV-infected men.
17 Study Design Multi-Site Cohort Study HIV + Men age > 18 followed in 1 of 7 CNICS sites from Serum testosterone levels, sociodemographic, lab, clinical and medication data, BMI, smoking, alcohol use, and race/ethnicity. Excluded men already taking TRT or within 30 days of cohort entry or unknown initiation date Medication, chart abstraction, EMRs and pharmacy data for initiation dates.
18 Study Design 2 TD = total testosterone < 300ng/dl free testosterone deficiency overlapped total testosterone We calculated TRT initiation rate as number of TRT initiation events per person-years (py) of follow-up time from cohort entry to initial TRT date, loss to follow-up, or death. TRT initiation predictors with univariable and multivariable Cox regression.
19 Results: Testosterone Supplementation 14,454 men without evidence of TRT prior to CNICS entry with 75,173 py of follow-up time. TRT was initiated in 1,482 (10%) men at a median age of 44 (IQR 38-51) years. The median time between cohort enrollment and TRT initiation was 868 days (IQR 280-1,907). Of the 1584 incident medications, 624 (39%) were intramuscular, 503 (32%) were transdermal, 1 (0.1%) was oral, and 456 (29%) were unspecified.
20 Results: TRT initiation We calculated a TRT initiation rate of 19.7/1,000 py (95% CI ). Higher rates of TRT initiation were associated with: age 35y, White race, MSM (HIV risk factor), diagnosis of AIDS wasting, protease inhibitor (PI)-based ART, nadir CD4+ T- lymphocyte cell count (CD4) 200 cells/mm 3, non-smoking, and absence of alcohol abuse.
21 Multivariate Predictors Age < 34 (HR 1.00) Age (HR 1.58, CI ) Age > 50 (HR 1.82, CI ) White Race (HR 1.72, CI ) AIDS Wasting (HR 2.07, CI ) Nadir CD4 < 200 cells/mm 3 (HR 1.23, CI ) PI based ART (HR 1.44, CI ) Hep C (HR 1.2, CI ) Not associated: MSM, Hep B, HIV viral load, BMI*, smoking or alcohol use
22 Assessment of Serum Testosterone 992 (67%) of the 1,482 men initiating TRT had pre-trt serum total testosterone level measured Median pre-treatment level was 358 (IQR ) ng/dl. Pre-TRT testosterone deficiency was found in 360 (24%). Serum total Testosterone was measured at least once after TRT initiation in 898 (61%) Median maximum post-trt level of 569 (IQR 370, 841) ng/dl. Median time to first post-trt serum total testosterone measurement was 303 (IQR 104, 885) days. The first post-trt serum total testosterone measurement occurred within six months of TRT initiation in 377 (25%) men.
23 PSA monitoring Over half (55%, 812/1,482) of those initiating TRT were above age 40. In this group, 273 (34%) and 97 (12%) had pre- and six month post-trt prostate specific antigen (PSA) measurements, respectively.
24 We did not track Hematocrit levels Side Effect monitoring Erectile Dysfunction Bone Mineral Density
25 Conclusions The rate of testosterone supplementation is higher than reported in the general population Treatment Is often not accompanied by appropriate laboratory testing Monitoring & follow up seem poor. Limitations: under-reporting of testosterone use, under-reporting of testosterone from outside labs, PSA controversies may effect clinical decisions
26 Next Steps Explore rates of prostate cancer, advanced prostate cancer and treatment initiation rates for BPH/LUTS after TRT in HIV+ men. Explore rates of non-fatal and fatal MI in CNICS cohort
27 References 1. Handelsman DJ. Global trends in testosterone prescribing, : expanding the spectrum of prescription drug misuse. Med J Aust 2013;199: Baillargeon J, Urban RJ, Ottenbacher KJ, Pierson KS, Goodwin JS. Trends in androgen prescribing in the United States, 2001 to JAMA Intern Med 2013;173: Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010;95: Katz A, Katz A, Burchill C. Androgen therapy: testing before prescribing and monitoring during therapy. Can Fam Physician 2007;53: Layton JB, Li D, Meier CR, Sharpless J, Sturmer T, Jick SS, et al. Testosterone Lab Testing and Initiation in the United Kingdom and the United States, J Cliin Endocrinol Metab 2014:jc Wolfe SM. Increased heart attacks in men using testosterone: the UK importantly lags far behind the US in prescribing testosterone. BMJ 2014;348:g Xu L, Freeman G, Cowling BJ, Schooling CM. Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials. BMC Med 2013;11: Basaria S, Coviello AD, Travison TG, Storer TW, Farwell WR, Jette AM, et al. Adverse events associated with testosterone administration. N Engl J Med 2010;363: Finkle WD, Greenland S, Ridgeway GK, Adams JL, Frasco MA, Cook MB, et al. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS One 2014;9:e Vigen R, O'Donnell CI, Baron AE, Grunwald GK, Maddox TM, Bradley SM, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA 2013;310: Glueck CJ, Wang P. Testosterone therapy, thrombosis, thrombophilia, cardiovascular events. Metabolism 2014;63: Crum NF, Furtek KJ, Olson PE, Amling CL, Wallace MR. A review of hypogonadism and erectile dysfunction among HIV-infected men during the pre- and post-haart eras: diagnosis, pathogenesis, and management. AIDS Patient Care STDS 2005;19: Wunder DM, Bersinger NA, Fux CA, Mueller NJ, Hirschel B, Cavassini M, et al. Hypogonadism in HIV-1-infected men is common and does not resolve during antiretroviral therapy. Antivir Ther 2007;12: Ashby J, Goldmeier D, Sadeghi-Nejad H. Hypogonadism in human immunodeficiency virus-positive men. Korean J Urol 2014;55: Dobs AS, Few WL, 3rd, Blackman MR, Harman SM, Hoover DR, Graham NM Serum hormones in men with human immunodeficiency virus-associated wasting. J Clin endocrinol Metab 81: Arver S, Sinba-Hikim I, Beall G, Guerrero M, Shen R, Bhasin S 1999, Serum dihydrotestosterone and testosterone concentrations in human immunodeficiency virusinfected men with and without weight loss. J Androl 20:
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.31 Subject: Testosterone Topical Page: 1 of 9 Last Review Date: September 23, 2016 Testosterone topical
Male Androgen Replacement Mitchell Sorsby, MD June 19, 2010. QUESTION # 1 Which of the following is not a symptom associated with low T levels? a) decreased libido b) erectile dysfunction c) depression
Testosterone Therapy in Men An update SANDEEP DHINDSA Associate Professor of Medicine Director, Division of Endocrinology and Metabolism, Saint Louis University, St. Louis, MO Presenter Disclosure None
Endocrine Update 2016 Mary T. Korytkowski MD Division of Endocrinology University of Pittsburgh Disclosure of Financial Relationships Mary Korytkowski MD Honoraria British Medical Journal Diabetes Research
GUIDELINES ON Male Hypogonadism G.R. Dohle, S. Arver,. Bettocchi, S. Kliesch, M. Punab, W. de Ronde Introduction Male hypogonadism is a clinical syndrome caused by androgen deficiency. It may adversely
Effects of Hormone Therapy on the Metabolic Syndrome and Cardiovascular Disease Micol S. Rothman, MD Associate Professor of Medicine Endocrinology, Diabetes and Metabolism Clinical Director Metabolic Bone
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.33 Subject: Testosterone Injection Implant Page: 1 of 10 Last Review Date: December 8, 2017 Testosterone
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.33 Subject: Testosterone Injection Implant Page: 1 of 10 Last Review Date: March 17, 2017 Testosterone
Point-Counterpoint: Late Onset Hypogonadism (LOH) We are Under-diagnosing and Treating Men with LOH LOH is a Non-existent Disease ~ Robert E. Donohue, MD Late Onset Hypogonadism LOH: underdx. & undertx
Late onset Hypogonadism Dr KhooSay Chuan Department of Urology Penang General Hospital Late onset hypogonadism(loh) Definition LOH age associated testoteronedeficiency syndrome (TDS) Male menopause, andropause,
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.08.37 Subject: Testosterone Powder Page: 1 of 11 Last Review Date: September 18, 2015 Testosterone powder
EFFICACY AND SAFETY OF TESTOSTERONE THERAPY FOR LATE-ONSET HYPOGONADISM: AN UPDATE Matthew Ho, PGY-2 Department of Urologic Sciences University of British Columbia OBJECTIVES 1. Review the characteristics
Take-Home Messages: Androgens Anthony J. Bella MD, FRCSC Greta and John Hansen Chair in Men s Health Research Division of Urology, Department of Surgery University of Ottawa SUMMARY SLAMS Symposium Clinical
Authoriser: Moya O Doherty Page 1 of 7 BIOCHEMICAL TESTS FOR THE INVESTIGATION OF COMMON ENDOCRINE PROBLEMS IN THE MALE The purpose of this protocol is to describe common tests used for the investigation
Androgen Replacement Therapy in the Aging Male Thomas J. Walsh, MD, MS Department of Urology University of California, San Francisco Objectives 1. List 3 effects of androgens on normal male physiology.
pissn: 2287-4208 / eissn: 2287-4690 World J Mens Health 2015 December 33(3): 130-142 http://dx.doi.org/10.5534/wjmh.2015.33.3.130 Review Article Testosterone Replacement Therapy and Cardiovascular Risk:
Can men on AS be treated with testosterone? Professor Bertrand Tombal, MD, PhD Cliniques universitaires Saint-Luc Université catholique de Louvain Brussels, Belgium Conflicts of interest PI or member steering
Evaluation and Treatment of Primary Androgen Deficiency Syndrome in Male Patients Jeff Unger, MD Director Chino Medical Group Diabetes and Headache Intervention Center Chino, California January 16, 2008
Preparing for the road ahead LEARN MORE ABOUT these 5 risks to A MAN S health 3 4 5 2 6 1 7 0 8 9 WHY DOES IT SEEM LIKE SOME MEN TAKE BETTER CARE OF THEIR CARS THAN THEIR OWN HEALTH? When the check engine
Recognizing and Managing Testosterone Deficiency J. Bruce Redmon, M.D. Professor Division of Endocrinology Departments of Medicine and Urologic Surgery Disclosure Information I have no financial relationships
4 4:4pm Testosterone Therapy: Examining the Evidence SPEAKER Culley Carson, MD Presenter Disclosure Information The following relationships exist related to this presentation: Culley Carson, MD: Consultant
ANDROGEN DEFICIENCY/MALE HYPOGONADISM 1. Medical Condition Hypogonadism in men is a clinical syndrome that results from failure of the testes to produce physiological levels of testosterone (androgen deficiency)
Is T for Me? Testosterone Replacement Therapy in Older Males Natalia Malesa, PharmD, MSIS PGY1 Community Pharmacy Resident H-E-B Pharmacy The University of Texas at Austin Objectives At the end of this
SMSNA Hypogonadism Colloquium: Update Arthur L. (Bud) Burnett, M.D., M.B.A., F.A.C.S. Patrick C. Walsh Distinguished Professor of Urology The James Buchanan Brady Urological Institute Johns Hopkins Medicine
Diagnosis and Clinical Evaluation of Hypogonadism in Adult Patients with Obesity and Diabetes Adrian Dobs, M.D., M.H.S. Professor of Medicine and Oncology The Johns Hopkins University School of Medicine
SPECIAL ARTICLE Adult-Onset Hypogonadism Mohit Khera, MD, MBA, MPH; Gregory A. Broderick, MD; Culley C. Carson III, MD; Adrian S. Dobs, MD, MHS; Martha M. Faraday, PhD; Irwin Goldstein, MD; Lawrence S.
Gomes et al. BMC Infectious Diseases (2016) 16:628 DOI 10.1186/s12879-016-1892-5 RESEARCH ARTICLE Prevalence of testosterone deficiency in HIV-infected men under antiretroviral therapy Ana Rita Gomes 1*,
Male Menopause: Disease or Pseudoscience? March 4, 2015 story: FDA to require warning on labels of testosterone products. 3-30-2015; web William E. Winter, MD University of Florida Departments of Pathology
Repeat Pregnancies and HIV Care Engagement among Postpartum HIV-infected Women in Atlanta, Georgia, 2011-2015 Anandi N. Sheth, Christina M. Meade, Martina Badell, Susan A. Davis, Stephanie Hackett, Joy
CANCER FOLLOWING COMBINATION ANTIRETROVIRAL THERAPY INITIATION: INCIDENCE PATTERNS AND EFFECTS OF ANTIRETROVIRAL RESPONSE Elizabeth L. Yanik, ScM A dissertation submitted to the faculty of the University
Estrogens vs Testosterone for cardiovascular health and longevity Panagiota Pietri, MD, PhD, FESC Director of Hypertension Unit Athens Medical Center Athens, Greece Women vs Men Is there a difference in
Tobias S. Kohler, MD, MPH, FACS Southern Illinois University School of Medicine AUA SMSNA Program May 7, 2016 Abbvie Researcher/Consultant/Grant Funding Boston Scientific Researcher/Consultant/Grant Funding
Review Article Off label therapies for testosterone replacement Lorenzo DiGiorgio 1, Hossein Sadeghi-Nejad 2 1 Division of Urology, Rutgers New Jersey Medical School, Newark, NJ, USA; 2 Hackensack University
Late Onset Hypogonadism Toh Charng Chee Hospital Selayang Introduction Although suppressed serum testosterone (T) is common in ageing men, only a small proportion of them develop the genuine syndrome of
ADULT UROLOGY PREVALENCE OF PROSTATE CANCER AMONG HYPOGONADAL MEN WITH PROSTATE-SPECIFIC ANTIGEN LEVELS OF 4.0 ng/ml OR LESS ABRAHAM MORGENTALER AND ERNANI LUIS RHODEN ABSTRACT Objectives. To determine
Clinical Policy: Reference Number: CA.CP.MP.507 Effective Date: 1/12 Last Review Date: 7/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory and
www.kjurology.org DOI:10.4111/kju.2011.52.6.416 Sexual Dysfunction Correlation between Serum Total Testosterone and the AMS and IIEF Questionnaires in Patients with Erectile Dysfunction with Testosterone
HIV Infection as a Chronic Disease Howard Libman, MD Beth Israel Deaconess Medical Center Harvard Medical School Role of Primary Care Approximately 50,000 patients are diagnosed with HIV infection annually
Report Back from CROI 2010 Conference on Retroviruses and Opportunistic Infections Edwin Charlebois, MPH PhD Associate Professor of Medicine Department of Medicine University of California, San Francisco
Changes in prostate-specific antigen and hormone levels following withdrawal of prolonged androgen ablation for prostate cancer S Egawa 1 *, H Okusa 1, K Matsumoto 1, K Suyama 1 & S Baba 1 1 Department
University of Vermont ScholarWorks @ UVM Family Medicine Clerkship Student Projects College of Medicine 2014 Low T? Late Onset Hypogonadism Cheng-Wei Huang University of Vermont Follow this and additional
Male hypogonadism & testosterone replacement therapy Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard Adverse events should also be reported
Physician Performance Measurement Set Approved May 2012 Endocrine Society 2055 L Street, NW, Suite 600 Washington, DC 20036 (P) 202-971-3636 (F) 202-736-9706 endocrine.org Background These clinical performance
Immediate ART in START Cuts Risk of Infection-Linked Cancer About 75% Conference on Retroviruses and Opportunistic Infections (CROI), February 22-25, 2016, Boston Mark Mascolini People who started antiretroviral
Brigham Young University BYU ScholarsArchive All Faculty Publications 2017-01-27 Comparison of Testosterone Replacement Therapy Medications for Treatment of Hypogonadism Karlen Beth Luthy Brigham Young
MALE HYPOGONADISM: CHOOSING THE APPROPRIATE THERAPY Michael S. Irwig, M.D. Director, Center for Andrology Division of Endocrinology & Metabolism Disclosures Aromatase inhibitors & clomiphene citrate are
open access Risk of erectile dysfunction associated with use of 5-α reductase inhibitors for benign prostatic hyperplasia or alopecia: population based studies using the Clinical Practice Research Datalink
European Urology Supplements European Urology Supplements 4 (2005) 16 23 Testosterone Substitution and the Prostate E. David Crawford* University of Colorado Health Sciences Center, 1665 N. Ursula Street,
METASTATIC PROSTATE CANCER MANAGEMENT K I R U B E L T E F E R A M. D. T R I H E A LT H C A N C E R I N S T I T U T E 0 1 / 3 1 / 2 0 1 8 Prostate Cancer- Statistics Most common cancer in men after a skin
Depression and Sexuality in Aging Men Prof. Dr. Michael Zitzmann Andrologist, Endocrinologist, Diabetologist Sexual Medicine (FECSM) Clinical Andrology / Centre for Reproductive Medicine and Andrology,
Chapter 4: Research and Future Directions Introduction Many of the future research needs listed in the 1994 Agency for Health Care Policy and Research (AHCPR) clinical practice guideline Benign Prostatic
ORIGINAL ARTICLE Vol. 42 (x): 2016 July 4.[Ahead of print] doi: 10.1590/S1677-5538.IBJU.2016.0112 Clomiphene citrate treatment for late onset hypogonadism: rise and fall Marcelo Marconi 1, Renato Souper
CHRONIC HEPATITIS B AND C COHORT STUDY (CHECS) CDC CONTACT Scott D Holmberg, M.D., M.P.H. Chief, Epidemiology and Surveillance Branch Division of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis,
LDL cholesterol and cardiovascular outcomes? Prof Kausik Ray, BSc (hons), MBChB, FRCP, MD, MPhil (Cantab), FACC, FESC Professor of Cardiovascular Disease Prevention St Georges University of London Honorary
NIH Public Access Author Manuscript Published in final edited form as: World J Urol. 2011 February ; 29(1): 11 14. doi:10.1007/s00345-010-0625-4. Significance of preoperative PSA velocity in men with low
Sexual Medicine Hypogonadal symptoms in young men are associated with a serum total testosterone threshold of 400 ng/dl Jason M. Scovell, Ranjith Ramasamy, Nathan Wilken, Jason R. Kovac and Larry I. Lipshultz
CROI 2016 Update NEAETC, March 21, 2016 Sigal Yawetz, MD Brigham and Women s Hospital Harvard Medical School CROI 2016 Update NEAETC, March 21, 2016 UNITED STATES EPIDEMIOLOGY Estimating the lifetime risk
The new england journal of medicine established in 1812 February 18, 2016 vol. 374 no. 7 Effects of Testosterone Treatment in Older Men P.J. Snyder, S. Bhasin, G.R. Cunningham, A.M. Matsumoto, A.J. Stephens
IMPROVING PATIENT CARE THROUGH ESOTERIC LABORATORY TESTING SEPTEMBER 2007 A Clinical Conundrum: The Diagnosis and Treatment of Androgen Deficiency in Older Men Testosterone replacement in young men with
Declaration of Conflict of Interest No potential conflict of interest to disclose with regard to the topics of this presentations. Clinical implications of smoking relapse after acute ischemic stroke Furio
CLINICAL SCIENCE Association of C-Reactive Protein and HIV Infection With Acute Myocardial Infarction Virginia A. Triant, MD, MPH,* James B. Meigs, MD, MPH, and Steven K. Grinspoon, MD Objective: To investigate
. 11 Mini Reviews UNPREDICTABILITY OF TESTOSTERONE THERAPY MORALES BJUI Effect of testosterone administration to men with prostate cancer is unpredictable: a word of caution and suggestions for a registry
The Healthy User Effect: Ubiquitous and Uncontrollable S. R. Majumdar, MD MPH FRCPC FACP Professor of Medicine, Endowed Chair in Patient Health Management, Health Scholar of the Alberta Heritage Foundation,
Case discussion: How do drugs/patients impact need and type of monitoring CASE 2 Marta Boffito Head of Clinical Trials, St. Stephen s Centre (SSAT) Consultant Physician, Chelsea and Westminster Foundation
Pharmacy Policy Class: Transgender Hormonal Treatment for Adults Line of Business: Medi-Cal Effective date: February 15, 2017 Revision date: February 15, 2017 This policy has been developed through review
Best Papers UROLOGY F. Fusco Best papers - 2015 RP/RT Oncological outcomes RP/RT IN ct3 Utilization trends RP/RT Complications Evolving role of elnd /Salvage LND This cohort reflects the current clinical
Anal cancer prevention strategies including screening for HPV-related diseases in HIV-positive patients Charles JN Lacey, Centre for Immunology and Infection, University of York, York, United Kingdom One
THE RECEPTOR Message from the Chair Hubert Vesper, PhD, Centers for Disease Control and Prevention Greetings! The 2015 AACC Annual Meeting begins very soon and I would like to take this time to encourage
A Randomized Trial of a Multivitamin (MVM) in the Prevention of Cardiovascular Disease in Men: The Physicians Health Study (PHS) II Presenter Disclosure Information Howard D. Sesso, ScD, MPH Relevant Disclosures:
ORIGINAL ARTICLE Neurol Med Chir (Tokyo) 54, 794 798, 2014 doi: 10.2176/nmc.oa.2014-0078 Online September 29, 2014 Effects of Testosterone Levels on Functional Recovery with Rehabilitation in Stroke Patients
Published 19 March 2012, doi:10.4414/smw.2012.13539 Cite this as: Testosterone treatment in the aging male: myth or reality? Nicole Nigro, Mirjam Christ-Crain Department of Endocrinology University Hospital